| 1 |
Climent C, Soriano S, Bonfill T, Lopez N, Rodriguez M, Sierra M, Andreu P, Fragio M, Busquets M, Carrasco A, Cano O, Seguí MA, Gallardo E. The role of immunotherapy in non-clear cell renal cell carcinoma. Front Oncol 2023;13:941835. [PMID: 36816976 DOI: 10.3389/fonc.2023.941835] [Reference Citation Analysis]
|
| 2 |
Kanwal R. Metastasis in renal cell carcinoma: Biology and treatment. Advances in Cancer Biology - Metastasis 2023. [DOI: 10.1016/j.adcanc.2023.100094] [Reference Citation Analysis]
|
| 3 |
Cimadamore A, Caliò A, Marandino L, Marletta S, Franzese C, Schips L, Amparore D, Bertolo R, Muselaers S, Erdem S, Ingels A, Pavan N, Pecoraro A, Kara Ö, Roussel E, Carbonara U, Campi R, Marchioni M; EAU-YAU Renal Cancer Working Group. Hot topics in renal cancer pathology: implications for clinical management. Expert Rev Anticancer Ther 2022;22:1275-87. [PMID: 36377655 DOI: 10.1080/14737140.2022.2145952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Hahn AW, Lebenthal J, Genovese G, Sircar K, Tannir NM, Msaouel P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun 2022;33:100640. [PMID: 36174377 DOI: 10.1016/j.ctarc.2022.100640] [Reference Citation Analysis]
|
| 5 |
Belikov AV, Vyatkin AD, Leonov SV. Novel Driver Strength Index highlights important cancer genes in TCGA PanCanAtlas patients. PeerJ 2022;10:e13860. [PMID: 35975235 DOI: 10.7717/peerj.13860] [Reference Citation Analysis]
|
| 6 |
Studentova H, Rusarova N, Ondruskova A, Zemankova A, Student V, Skanderova D, Melichar B. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature. Current Oncology 2022;29:5475-5488. [DOI: 10.3390/curroncol29080433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Xu W, Anwaier A, Liu W, Wei G, Su J, Tian X, Xia J, Qu Y, Zhao J, Zhang H, Ye D. Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma. Front Immunol 2022;13:953721. [DOI: 10.3389/fimmu.2022.953721] [Reference Citation Analysis]
|
| 8 |
Angori S, Lobo J, Moch H. Papillary renal cell carcinoma: current and controversial issues. Curr Opin Urol 2022;32:344-51. [PMID: 35674688 DOI: 10.1097/MOU.0000000000001000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 9 |
Fontes-sousa M, Calvo E. First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Lee E, Guan P, Lim AH, Loh JW, Tan GF, Loh T, Ng DYX, Lee JY, Goh S, Liu W, Ng CC, Teh BT, Chan JY. Multiregion sequencing of sarcomatoid renal cell carcinoma arising from autosomal dominant polycystic kidney disease. Mol Genet Genomic Med 2022;:e1853. [PMID: 35122417 DOI: 10.1002/mgg3.1853] [Reference Citation Analysis]
|
| 11 |
An J, Packiam VT, Chennamadhavuni A, Richards J, Jain J, Mott SL, Garje R. Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma. Front Oncol 2021;11:786307. [PMID: 35083144 DOI: 10.3389/fonc.2021.786307] [Reference Citation Analysis]
|
| 12 |
Ravindranathan D, Alhalabi O, Rafei H, Shah AY, Bilen MA. Landscape of Immunotherapy in Genitourinary Malignancies. Adv Exp Med Biol 2021;1342:143-92. [PMID: 34972965 DOI: 10.1007/978-3-030-79308-1_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Goebell PJ. Molekulares Tumorboard – Nierenzellkarzinom. Die Urologie 2022. [DOI: 10.1007/978-3-642-41168-7_252-1] [Reference Citation Analysis]
|
| 14 |
Candelario N, Geiger C, Flaig T. Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms. KCA 2021;5:167-79. [DOI: 10.3233/kca-210126] [Reference Citation Analysis]
|
| 15 |
Agaimy A, Hartmann A, Trpkov K, Hes O. Undifferentiated and dedifferentiated urological carcinomas: lessons learned from the recent developments. Semin Diagn Pathol 2021;38:152-62. [PMID: 34579992 DOI: 10.1053/j.semdp.2021.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Ding L, Dong HY, Zhou TR, Wang YH, Yan T, Li JC, Wang ZY, Li J, Liang C. PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies. Cancer Med 2021. [PMID: 34382349 DOI: 10.1002/cam4.4190] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 17 |
Belikov AV, Otnyukov DV, Vyatkin AD, Leonov SV. Novel Driver Strength Index highlights important cancer genes in TCGA PanCanAtlas patients.. [DOI: 10.1101/2021.08.01.21261447] [Reference Citation Analysis]
|
| 18 |
Zhang C, Feng S, Tu Z, Sun J, Rui T, Zhang X, Huang H, Ling Q, Zheng S. Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome. Cancer Med 2021. [PMID: 34331411 DOI: 10.1002/cam4.4162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 19 |
Trpkov K, Hes O, Williamson SR, Adeniran AJ, Agaimy A, Alaghehbandan R, Amin MB, Argani P, Chen YB, Cheng L, Epstein JI, Cheville JC, Comperat E, da Cunha IW, Gordetsky JB, Gupta S, He H, Hirsch MS, Humphrey PA, Kapur P, Kojima F, Lopez JI, Maclean F, Magi-Galluzzi C, McKenney JK, Mehra R, Menon S, Netto GJ, Przybycin CG, Rao P, Rao Q, Reuter VE, Saleeb RM, Shah RB, Smith SC, Tickoo S, Tretiakova MS, True L, Verkarre V, Wobker SE, Zhou M, Gill AJ. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol 2021;34:1392-424. [PMID: 33664427 DOI: 10.1038/s41379-021-00779-w] [Cited by in Crossref: 86] [Cited by in F6Publishing: 89] [Article Influence: 43.0] [Reference Citation Analysis]
|
| 20 |
Yakirevich E, Pavlick DC, Perrino CM, Stanton M, Lu S, Carneiro B, Bratslavsky G, Ross JS. NF2 Tumor Suppressor Gene Inactivation in Advanced Papillary Renal Cell Carcinoma. Am J Surg Pathol 2021;45:716-8. [PMID: 32925192 DOI: 10.1097/PAS.0000000000001586] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 21 |
Patel HV, Srivastava A, Srinivasan R, Singer EA. A challenging frontier - the genomics and therapeutics of nonclear cell renal cell carcinoma. Curr Opin Oncol 2021;33:212-20. [PMID: 33818540 DOI: 10.1097/CCO.0000000000000721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 22 |
Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol 2021;17:245-61. [PMID: 33144689 DOI: 10.1038/s41581-020-00359-2] [Cited by in Crossref: 139] [Cited by in F6Publishing: 137] [Article Influence: 69.5] [Reference Citation Analysis]
|
| 23 |
Adashek JJ, Zhang Y, Skelton WP 4th, Bilotta A, Chahoud J, Zemp L, Li J, Dhillon J, Manley B, Spiess PE. Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation? Front Oncol 2020;10:627025. [PMID: 33643921 DOI: 10.3389/fonc.2020.627025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 24 |
Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Tang S, Bosma-Moody A, He MX, Vokes N, Nyman J, Xie W, Nassar AH, Abou Alaiwi S, Flippot R, Bouchard G, Steinharter JA, Nuzzo PV, Ficial M, Sant'Angelo M, Forman J, Berchuck JE, Dudani S, Bi K, Park J, Camp S, Sticco-Ivins M, Hirsch L, Baca SC, Wind-Rotolo M, Ross-Macdonald P, Sun M, Lee GM, Chang SL, Wei XX, McGregor BA, Harshman LC, Genovese G, Ellis L, Pomerantz M, Hirsch MS, Freedman ML, Atkins MB, Wu CJ, Ho TH, Linehan WM, McDermott DF, Heng DYC, Viswanathan SR, Signoretti S, Van Allen EM, Choueiri TK. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun 2021;12:808. [PMID: 33547292 DOI: 10.1038/s41467-021-21068-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 17.5] [Reference Citation Analysis]
|
| 25 |
Carbone F, Huang JK, Perelli L, Poggetto ED, Gutschner T, Tomihara H, Soeung M, Lam TNA, Xia R, Zhu C, Song X, Zhang J, Sircar K, Malouf GG, Sgambato A, Karam JA, Gao J, Jonasch E, Viale A, Draetta GF, Futreal A, Bakouny Z, Van Allen EM, Choueiri T, Msaouel P, Litchfield K, Turajlic S, Heffernan TP, Chen YB, Dinatale RG, Hakimi AA, Bristow CA, Tannir NM, Carugo A, Genovese G. 9p21 Loss Defines the Evolutionary Patterns of Aggressive Renal Cell Carcinomas.. [DOI: 10.1101/2020.11.03.367433] [Reference Citation Analysis]
|
| 26 |
Zhi H, Feng M, Liu S, Na T, Zhang N, BiLiGe W. Prognostic Significance of Sarcomatoid Differentiation in Patients With Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:591001. [PMID: 33134181 DOI: 10.3389/fonc.2020.591001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 27 |
Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, Karam JA, Hakimi AA. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol 2020;17:659-78. [PMID: 33051619 DOI: 10.1038/s41585-020-00382-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 28 |
Dudek AZ, Baxstrom K, Bharadwaj S, Blaes A, Kulkarni A, Lou E, Nehru V, Rabinovich E, Shergill A, Viner M. Genomic Strategies for Personalized Cancer Therapy. Precision Medicine in Oncology 2020. [DOI: 10.1002/9781119432487.ch1] [Reference Citation Analysis]
|
| 29 |
Testa U, Pelosi E, Castelli G. Genetic Alterations in Renal Cancers: Identification of The Mechanisms Underlying Cancer Initiation and Progression and of Therapeutic Targets. Medicines (Basel) 2020;7:E44. [PMID: 32751108 DOI: 10.3390/medicines7080044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 30 |
Iacovelli R, Ciccarese C, Bria E, Bracarda S, Porta C, Procopio G, Tortora G. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. Eur J Cancer 2020;136:195-203. [PMID: 32712550 DOI: 10.1016/j.ejca.2020.06.008] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 31 |
Chen SL, Huang QS, Huang YH, Yang X, Yang MM, He YF, Cao Y, Guan XY, Yun JP. GYS1 induces glycogen accumulation and promotes tumor progression via the NF-κB pathway in Clear Cell Renal Carcinoma. Theranostics 2020;10:9186-99. [PMID: 32802186 DOI: 10.7150/thno.46825] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 32 |
Grilo I, Rodrigues C, Soares A, Grande E. Facing treatment of non-urothelial bladder cancers in the immunotherapy era. Crit Rev Oncol Hematol 2020;153:103034. [PMID: 32622321 DOI: 10.1016/j.critrevonc.2020.103034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 33 |
Dizman N, Philip EJ, Pal SK. Genomic profiling in renal cell carcinoma. Nat Rev Nephrol 2020;16:435-51. [PMID: 32561872 DOI: 10.1038/s41581-020-0301-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 15.3] [Reference Citation Analysis]
|
| 34 |
Attalla K, Weng S, Voss MH, Hakimi AA. Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma. Urol Clin North Am 2020;47:293-303. [PMID: 32600532 DOI: 10.1016/j.ucl.2020.04.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 35 |
Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Tang S, Bosma-moody A, He MX, Vokes N, Nyman J, Xie W, Nassar AH, Alaiwi SA, Flippot R, Bouchard G, Steinharter JA, Nuzzo PV, Ficial M, Sant’angelo M, Forman J, Berchuck JE, Dudani S, Bi K, Park J, Camp S, Sticco-ivins M, Hirsch L, Wind-rotolo M, Ross-macdonald P, Sun M, Lee GM, Chang SL, Wei XX, Mcgregor BA, Harshman LC, Genovese G, Ellis L, Pomerantz M, Hirsch MS, Freedman ML, Atkins MB, Wu CJ, Ho TH, Linehan WM, Mcdermott DF, Heng DY, Viswanathan SR, Signoretti S, Van Allen EM, Choueiri TK. Integrative Molecular Characterization of Sarcomatoid and Rhabdoid Renal Cell Carcinoma Reveals Determinants of Poor Prognosis and Response to Immune Checkpoint Inhibitors.. [DOI: 10.1101/2020.05.28.121806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 36 |
Braun DA, Hou Y, Bakouny Z, Ficial M, Sant' Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, Steinharter J, Sun M, Wind-Rotolo M, Pignon JC, Cherniack AD, Lichtenstein L, Neuberg D, Catalano P, Freeman GJ, Sharpe AH, McDermott DF, Van Allen EM, Signoretti S, Wu CJ, Shukla SA, Choueiri TK. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med 2020;26:909-18. [PMID: 32472114 DOI: 10.1038/s41591-020-0839-y] [Cited by in Crossref: 227] [Cited by in F6Publishing: 245] [Article Influence: 75.7] [Reference Citation Analysis]
|
| 37 |
Boustany J, Abdessater M, Hachem CE, Khoury ZE, Khoury WE, Khoury RE. Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib. Oncotarget 2020;11:1922-8. [PMID: 32499875 DOI: 10.18632/oncotarget.27543] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 38 |
Deleuze A, Saout J, Dugay F, Peyronnet B, Mathieu R, Verhoest G, Bensalah K, Crouzet L, Laguerre B, Belaud-Rotureau MA, Rioux-Leclercq N, Kammerer-Jacquet SF. Immunotherapy in Renal Cell Carcinoma: The Future Is Now. Int J Mol Sci 2020;21:E2532. [PMID: 32260578 DOI: 10.3390/ijms21072532] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 21.0] [Reference Citation Analysis]
|
| 39 |
Gulati S, Philip E, Salgia S, Pal SK. Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma. Cancer Treat Res Commun 2020;23:100172. [PMID: 32252014 DOI: 10.1016/j.ctarc.2020.100172] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 40 |
Hwang HS, Park YY, Shin SJ, Go H, Park JM, Yoon SY, Lee JL, Cho YM. Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma. J Korean Med Sci 2020;35:e31. [PMID: 32030920 DOI: 10.3346/jkms.2020.35.e31] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 41 |
Bacon JVW, Annala M, Soleimani M, Lavoie JM, So A, Gleave ME, Fazli L, Wang G, Chi KN, Kollmannsberger CK, Wyatt AW, Nappi L. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer 2020;18:322-331.e2. [PMID: 32046920 DOI: 10.1016/j.clgc.2019.12.018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 42 |
White SM, Avantaggiati ML, Nemazanyy I, Di Poto C, Yang Y, Pende M, Gibney GT, Ressom HW, Field J, Atkins MB, Yi C. YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells. Dev Cell 2019;49:425-443.e9. [PMID: 31063758 DOI: 10.1016/j.devcel.2019.04.014] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 13.7] [Reference Citation Analysis]
|
| 43 |
Dara Y, Salgia N, Pal SK. Renal Cell Carcinoma. Oncology in the Precision Medicine Era 2020. [DOI: 10.1007/978-3-030-31471-2_8] [Reference Citation Analysis]
|
| 44 |
Alhalabi O, Rafei H, Bilen MA, Shah AY. Current Landscape of Immunotherapy in Genitourinary Malignancies. Advances in Experimental Medicine and Biology 2020. [DOI: 10.1007/978-3-030-41008-7_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 45 |
Divatia MK, Guo CC, Rehman A, Ro JY. Major Subtypes of Renal Cell Carcinoma. Kidney Cancer 2020. [DOI: 10.1007/978-3-030-28333-9_5] [Reference Citation Analysis]
|
| 46 |
de Lima Guido LP, Hanly F, Escobedo B, Pinto A, Jorda M. Ancillary Studies Applied to Renal Masses. Renal Mass Biopsy 2020. [DOI: 10.1007/978-3-030-36036-8_12] [Reference Citation Analysis]
|
| 47 |
Debien V, Thouvenin J, Lindner V, Barthélémy P, Lang H, Flippot R, Malouf GG. Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities. Cancers (Basel) 2019;12:E99. [PMID: 31906050 DOI: 10.3390/cancers12010099] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 48 |
Rebuzzi SE, Perrone F, Bersanelli M, Bregni G, Milella M, Buti S. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Mol Diagn 2020;20:169-85. [PMID: 31608727 DOI: 10.1080/14737159.2019.1680286] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 49 |
de Cubas AA, Rathmell WK. Epigenetic modifiers: activities in renal cell carcinoma. Nat Rev Urol 2018;15:599-614. [PMID: 30030490 DOI: 10.1038/s41585-018-0052-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 50 |
Gupta S, Cheville JC, Jungbluth AA, Zhang Y, Zhang L, Chen YB, Tickoo SK, Fine SW, Gopalan A, Al-Ahmadie HA, Sirintrapun SJ, Blum KA, Lohse CM, Hakimi AA, Thompson RH, Leibovich BC, Berger MF, Arcila ME, Ross DS, Ladanyi M, Antonescu CR, Reuter VE. JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management. Mod Pathol 2019;32:1344-58. [PMID: 30996253 DOI: 10.1038/s41379-019-0269-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 51 |
Massari F, Di Nunno V, Santoni M, Gatto L, Caserta C, Morelli F, Zafarana E, Carrozza F, Mosca A, Mollica V, Iacovelli R, Sabbatini R, Porta C, Bracarda S. Toward a genome-based treatment landscape for renal cell carcinoma. Crit Rev Oncol Hematol 2019;142:141-52. [PMID: 31401421 DOI: 10.1016/j.critrevonc.2019.07.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 52 |
Park I, Lee HJ, Bae WK, Yoon S, Lee JL. A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component. Invest New Drugs 2019;37:1239-46. [DOI: 10.1007/s10637-019-00817-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 53 |
Grünwald V, Doehn C, Goebell PJ. [Molecular tumor board-renal cell carcinoma]. Urologe A 2019;58:768-73. [PMID: 31175376 DOI: 10.1007/s00120-019-0965-7] [Reference Citation Analysis]
|
| 54 |
Kammerer-Jacquet SF, Deleuze A, Saout J, Mathieu R, Laguerre B, Verhoest G, Dugay F, Belaud-Rotureau MA, Bensalah K, Rioux-Leclercq N. Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma. Int J Mol Sci. 2019;20:1692. [PMID: 30987368 DOI: 10.3390/ijms20071692] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 55 |
Delahunt B, Eble JN, Egevad L, Samaratunga H. Grading of renal cell carcinoma. Histopathology. 2019;74:4-17. [PMID: 30565310 DOI: 10.1111/his.13735] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 18.8] [Reference Citation Analysis]
|
| 56 |
Pichler R, Compérat E, Klatte T, Pichler M, Loidl W, Lusuardi L, Schmidinger M. Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope? Cancers (Basel) 2019;11:E422. [PMID: 30934624 DOI: 10.3390/cancers11030422] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 57 |
Pang JS, Li ZK, Lin P, Wang XD, Chen G, Yan HB, Li SH. The underlying molecular mechanism and potential drugs for treatment in papillary renal cell carcinoma: A study based on TCGA and Cmap datasets. Oncol Rep 2019;41:2089-102. [PMID: 30816528 DOI: 10.3892/or.2019.7014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 58 |
Cheng Y, Wang K, Geng L, Sun J, Xu W, Liu D, Gong S, Zhu Y. Identification of candidate diagnostic and prognostic biomarkers for pancreatic carcinoma. EBioMedicine 2019;40:382-93. [PMID: 30639415 DOI: 10.1016/j.ebiom.2019.01.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 59 |
Delphine B, Damien A, Philippe B. Renal Cell Carcinoma with Sarcomatoid Features. Rare Kidney Tumors 2019. [DOI: 10.1007/978-3-319-96989-3_9] [Reference Citation Analysis]
|
| 60 |
Di Nunno V, Gatto L, Fragomeno B, Cubelli M, Nobili E, Romano I, Santoni M, Pisconti S, Montironi R, Massari F. Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back? Future Oncology 2018;14:2997-9. [DOI: 10.2217/fon-2018-0604] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 61 |
D'Avella C, Abbosh P, Pal SK, Geynisman DM. Mutations in renal cell carcinoma. Urol Oncol 2020;38:763-73. [PMID: 30478013 DOI: 10.1016/j.urolonc.2018.10.027] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 62 |
Wang Z, Zeng X, Chen R, Chen Z. Ki-67 index and percentage of sarcomatoid differentiation were two independent prognostic predictors in sarcomatoid renal cell carcinoma. Cancer Manag Res 2018;10:5339-47. [PMID: 30464630 DOI: 10.2147/CMAR.S176242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 63 |
Lopez-Beltran A, Henriques V, Cimadamore A, Santoni M, Cheng L, Gevaert T, Blanca A, Massari F, Scarpelli M, Montironi R. The Identification of Immunological Biomarkers in Kidney Cancers. Front Oncol 2018;8:456. [PMID: 30450335 DOI: 10.3389/fonc.2018.00456] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 64 |
Albiges L, Flippot R, Rioux-Leclercq N, Choueiri TK. Non-Clear Cell Renal Cell Carcinomas: From Shadow to Light. J Clin Oncol 2018;:JCO2018792531. [PMID: 30372389 DOI: 10.1200/JCO.2018.79.2531] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 65 |
Massari F, Santoni M, Di Nunno V, Cimadamore A, Battelli N, Scarpelli M, Cheng M, Lopez-beltran A, Cheng L, Montironi R. Quick steps toward precision medicine in renal cell carcinoma. Expert Review of Precision Medicine and Drug Development 2018;3:283-285. [DOI: 10.1080/23808993.2018.1510289] [Reference Citation Analysis]
|
| 66 |
Lebacle C, Pooli A, Bessede T, Irani J, Pantuck AJ, Drakaki A. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art. World J Urol 2019;37:115-23. [PMID: 29858701 DOI: 10.1007/s00345-018-2355-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 67 |
Hou W, Ji Z. Generation of autochthonous mouse models of clear cell renal cell carcinoma: mouse models of renal cell carcinoma. Exp Mol Med 2018;50:1-10. [PMID: 29651023 DOI: 10.1038/s12276-018-0059-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 68 |
Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T, O'Brien T, Lopez JI, Watkins TBK, Nicol D, Stares M, Challacombe B, Hazell S, Chandra A, Mitchell TJ, Au L, Eichler-Jonsson C, Jabbar F, Soultati A, Chowdhury S, Rudman S, Lynch J, Fernando A, Stamp G, Nye E, Stewart A, Xing W, Smith JC, Escudero M, Huffman A, Matthews N, Elgar G, Phillimore B, Costa M, Begum S, Ward S, Salm M, Boeing S, Fisher R, Spain L, Navas C, Grönroos E, Hobor S, Sharma S, Aurangzeb I, Lall S, Polson A, Varia M, Horsfield C, Fotiadis N, Pickering L, Schwarz RF, Silva B, Herrero J, Luscombe NM, Jamal-Hanjani M, Rosenthal R, Birkbak NJ, Wilson GA, Pipek O, Ribli D, Krzystanek M, Csabai I, Szallasi Z, Gore M, McGranahan N, Van Loo P, Campbell P, Larkin J, Swanton C; TRACERx Renal Consortium. Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. Cell 2018;173:595-610.e11. [PMID: 29656894 DOI: 10.1016/j.cell.2018.03.043] [Cited by in Crossref: 322] [Cited by in F6Publishing: 256] [Article Influence: 64.4] [Reference Citation Analysis]
|
| 69 |
Liang X, Liu Y, Ran P, Tang M, Xu C, Zhu Y. Sarcomatoid renal cell carcinoma: a case report and literature review. BMC Nephrol 2018;19:84. [PMID: 29636020 DOI: 10.1186/s12882-018-0884-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 70 |
Song E, Song W, Ren M, Xing L, Ni W, Li Y, Gong M, Zhao M, Ma X, Zhang X, An R. Identification of potential crucial genes associated with carcinogenesis of clear cell renal cell carcinoma. J Cell Biochem 2018;119:5163-74. [PMID: 29227586 DOI: 10.1002/jcb.26543] [Cited by in Crossref: 27] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 71 |
Manley BJ, Hakimi AA. Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact. Curr Opin Urol 2016;26:383-7. [PMID: 27467134 DOI: 10.1097/MOU.0000000000000307] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 72 |
Jamal M, Taneja K, Arora S, Barod R, Rogers CG, Sanchez J, Gupta NS, Williamson SR. Chromophobe Renal Cell Carcinoma With Retrograde Venous Invasion and Gain of Chromosome 21: Potential Harbingers of Aggressive Clinical Behavior. Int J Surg Pathol 2018;26:536-41. [DOI: 10.1177/1066896918763948] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 73 |
Achkar T, Ali SM, Welsh A, Dhir R, Gollin SM, Parikh RA. A prolonged response to platinum-based therapy in a patient with metastatic urothelial carcinoma harboring a single rearranged and truncated NF2 gene. Genes Chromosomes Cancer 2018;57:430-3. [PMID: 29532557 DOI: 10.1002/gcc.22537] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 74 |
Abdel-rahman O. Impact of histological subtype on outcomes of renal cell carcinoma patients. Journal of Drug Assessment 2018;7:14-20. [DOI: 10.1080/21556660.2018.1439831] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 75 |
Hsieh JJ, Le V, Cao D, Cheng EH, Creighton CJ. Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision. J Pathol. 2018;244:525-537. [PMID: 29266437 DOI: 10.1002/path.5022] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 76 |
Mouallem NE, Smith SC, Paul AK. Sarcomatoid renal cell carcinoma: Biology and treatment advances. Urol Oncol 2018;36:265-71. [PMID: 29306556 DOI: 10.1016/j.urolonc.2017.12.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 77 |
Giles RH, Choueiri TK, Heng DY, Albiges L, Hsieh JJ, Linehan WM, Pal S, Maskens D, Paseman B, Jonasch E, Malouf G, Molina AM, Pickering L, Shuch B, Srinivas S, Srinivasan R, Tannir NM, Bex A. Recommendations for the Management of Rare Kidney Cancers. European Urology 2017;72:974-83. [DOI: 10.1016/j.eururo.2017.06.040] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 78 |
Zhang T, Gong J, Maia MC, Pal SK. Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma. Am Soc Clin Oncol Educ Book 2017;37:337-42. [PMID: 28561708 DOI: 10.1200/EDBK_175572] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 79 |
Salgia M, Adashek J, Bergerot P, Pal SK. Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice. Kidney Cancer 2017;1:99-105. [PMID: 30334011 DOI: 10.3233/KCA-170019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 80 |
Favazza L, Chitale DA, Barod R, Rogers CG, Kalyana-Sundaram S, Palanisamy N, Gupta NS, Williamson SR. Renal cell tumors with clear cell histology and intact VHL and chromosome 3p: a histological review of tumors from the Cancer Genome Atlas database. Mod Pathol 2017;30:1603-12. [PMID: 28731045 DOI: 10.1038/modpathol.2017.72] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 81 |
Sanfrancesco JM, Cheng L. Complexity of the genomic landscape of renal cell carcinoma: Implications for targeted therapy and precision immuno-oncology. Critical Reviews in Oncology/Hematology 2017;119:23-8. [DOI: 10.1016/j.critrevonc.2017.09.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 82 |
Inamura K. Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification. Int J Mol Sci 2017;18:E2195. [PMID: 29053609 DOI: 10.3390/ijms18102195] [Cited by in Crossref: 74] [Cited by in F6Publishing: 82] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 83 |
Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer 2017;123:4823-31. [PMID: 28832979 DOI: 10.1002/cncr.30937] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 84 |
Sanfrancesco JM, Eble JN, Grignon DJ, Wang M, Zhang S, Sundaram CP, Idrees MT, Pili R, Kouba E, Cheng L. Preservation of truncal genomic alterations in clear cell and papillary renal cell carcinomas with sarcomatoid features: An intra- and intertumoral, multifocal fluorescence in situ hybridization analysis reveals limited genetic heterogeneity. Mol Carcinog 2017;56:2527-37. [DOI: 10.1002/mc.22699] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 85 |
Wang Z, Kim TB, Peng B, Karam J, Creighton C, Joon A, Kawakami F, Trevisan P, Jonasch E, Chow CW, Canales JR, Tamboli P, Tannir N, Wood C, Monzon F, Baggerly K, Varella-Garcia M, Czerniak B, Wistuba I, Mills G, Shaw K, Chen K, Sircar K. Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. Clin Cancer Res 2017;23:6686-96. [PMID: 28710314 DOI: 10.1158/1078-0432.CCR-17-1057] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 86 |
Shapiro DD, Abel EJ. Editorial Comment. J Urol 2017;198:537. [PMID: 28641080 DOI: 10.1016/j.juro.2017.04.116] [Reference Citation Analysis]
|
| 87 |
Wei S, Al-Saleem T. The Pathology and Molecular Genetics of Sarcomatoid Renal Cell Carcinoma: A Mini-Review. J Kidney Cancer VHL 2017;4:19-23. [PMID: 28725540 DOI: 10.15586/jkcvhl.2017.70] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 88 |
Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN Jr, Tannir NM. A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma. Ann Oncol 2017;28:804-8. [PMID: 28049139 DOI: 10.1093/annonc/mdw676] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 89 |
de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. Clin Genitourin Cancer 2017;15:652-660.e1. [PMID: 28410911 DOI: 10.1016/j.clgc.2017.03.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 90 |
Schrock AB, Li SD, Frampton GM, Suh J, Braun E, Mehra R, Buck SC, Bufill JA, Peled N, Karim NA, Hsieh KC, Doria M, Knost J, Chen R, Ou SI, Ross JS, Stephens PJ, Fishkin P, Miller VA, Ali SM, Halmos B, Liu JJ. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. J Thorac Oncol. 2017;12:932-942. [PMID: 28315738 DOI: 10.1016/j.jtho.2017.03.005] [Cited by in Crossref: 84] [Cited by in F6Publishing: 100] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 91 |
Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Renal cell carcinoma. Nat Rev Dis Primers 2017;3:17009. [PMID: 28276433 DOI: 10.1038/nrdp.2017.9] [Cited by in Crossref: 1159] [Cited by in F6Publishing: 1239] [Article Influence: 193.2] [Reference Citation Analysis]
|
| 92 |
Gu L, Li H, Wang H, Ma X, Wang L, Chen L, Zhao W, Zhang Y, Zhang X. Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma. J Cancer Res Clin Oncol 2017;143:499-508. [DOI: 10.1007/s00432-016-2304-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 93 |
Haake SM, Rathmell WK. Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making? Cancer 2017;123:200-9. [PMID: 27861752 DOI: 10.1002/cncr.30314] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 94 |
Kouba EJ, Eble JN, Simper N, Grignon DJ, Wang M, Zhang S, Wang L, Martignoni G, Williamson SR, Brunelli M, Luchini C, Calió A, Cheng L. High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas: implications for tumor clonal evolution and treatment. Mod Pathol 2016;29:1347-57. [PMID: 27469331 DOI: 10.1038/modpathol.2016.133] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 95 |
Riazalhosseini Y, Lathrop M. Precision medicine from the renal cancer genome. Nat Rev Nephrol 2016;12:655-66. [DOI: 10.1038/nrneph.2016.133] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 96 |
Gong J, Maia MC, Dizman N, Govindarajan A, Pal SK. Metastasis in renal cell carcinoma: Biology and implications for therapy. Asian J Urol. 2016;3:286-292. [PMID: 29264197 DOI: 10.1016/j.ajur.2016.08.006] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 10.6] [Reference Citation Analysis]
|
| 97 |
Manley BJ, Hsieh JJ. Sarcomatoid renal cell carcinoma: genomic insights from sequencing of matched sarcomatous and carcinomatous components. Transl Cancer Res 2016;5:S160-5. [PMID: 29167760 DOI: 10.21037/tcr.2016.07.30] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
